NuCana is trading up 7.5% at $1.14 on October 6, 2026, with no clear company-specific catalyst identified.
- Searches found no clear company-specific announcement or reliable report linking a catalyst to the move; the European patent news and second-quarter update predate this session.
- Supplied sector context says biotech is down, while broad-market indices are higher; neither establishes a direct explanation.
- Available evidence does not support attributing the gain to company, sector, or global factors.